Form 4: Cullinan Therapeutics' Chief Scientific Officer Jennifer Michaelson Sells 8,000 Shares

Jennifer Michaelson, Chief Scientific Officer of Cullinan Therapeutics, sold 8,000 shares of common stock on November 5, 2024, at a weighted average price of $15.64.

Summary

• On November 5, 2024, Jennifer Michaelson, the Chief Scientific Officer of Cullinan Therapeutics, Inc. (CGEM), sold 8,000 shares of the company's common stock.
• The transaction was executed at a weighted average price of $15.64 per share, with individual sales prices ranging from $15.25 to $15.98.
• Following the reported transaction, Michaelson directly owns 107,942 shares of Cullinan Therapeutics.
• The sale was conducted under a pre-arranged trading plan established on January 5, 2024, in accordance with Rule 10b5-1.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a stock sale by an officer. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It provides transparency into the transactions of company executives and their holdings in the company. Investors often monitor these filings to gain insights into management's perspective on the company's stock and future prospects.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The information provided is consistent with regulatory requirements for disclosing changes in beneficial ownership.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, depending on their interpretation of the transaction.
• The sale represents a small percentage of the total outstanding shares and may not significantly affect the company's stock price.

Key Dates